Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-074-4 | CAS number: 103-05-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Read-across to PEA (CAS No. 60-12-8) - Repeated dose toxicity (dermal, subchronic): NOEL = 500 mg/kg bw/day (Equivalent or similar to OECD 411)
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- Please see read-across justification.
- Reason / purpose for cross-reference:
- read-across source
- Dose descriptor:
- NOEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
- Conclusions:
- In a 90 day sub-chronic toxicity study in Charles River CD albino rats, the NOEL value (males/females) for PEA was 500 mg/kg bw/day based on the changes in body weights.
- Executive summary:
In a 90 day sub-chronic toxicity study (equivalent or similar to OECD 411), PEA (99.9%) was administered to four groups of Charles River CD albino rats (15 animals/sex/group) dermally at dose levels of 0, 0.25, 0.5, 1.0, or 2.0 mL/kg (equivalent to 0, 250, 500, 1000, or 2000 mg/kg bw/day), 7 days per week, for 90 days. No deaths occurred during the treatment period and clinical examinations did not reveal abnormalities or differences among the groups. Among animals treated with 1000 and 2000 mg/kg bw/day body weights were decreased significantly after 1 wk of treatment and remained so for the duration of the experiment. After 90 days, the mean body-weight gains of rats treated with 0, 250, 500, 1000, or 2000 mg/kg bw/day were 260, 249, 248, 218 and 218 g, respectively, for the males and 98, 93, 87, 78 and 70g for the females. The mean body-weight gains of both sexes were depressed among treated animals in a dose-dependent fashion and the decreases were statistically significant at 1000 and 2000 mg/kg bw/day. There were no differences in the amounts of food consumed by the groups; thus, treated animals consumed a significantly greater amount of food relative to the gain in body weight than did the control animals.
Ophthalmological examination revealed no changes in either the fundus or anterior segment. Haematological results indicated a significant decrease in haemoglobin concentration and white blood cell count at week 6 and 13 among male rats dosed with 2000 mg/kg bw/day. Blood biochemistry or urinary analyses was not significantly affected among the groups at any of the assessment periods. Significant increases in the relative weights of the brain, kidneys and gonads occurred among rats of both sexes given 2000 mg/kg bw/day. Relative liver weights were increased at all doses among the females and both absolute and relative liver weights were decreased among the males given 1000 mg/kg bw/day. The elevations in relative organ weights while absolute values remained unchanged were related to decreases in body weight, particularly among animals dosed with 1000 mg/kg bw/day or 2000 mg/kg bw/day. The decrease in both absolute and relative liver weights in males treated with 1000 mg/kg bw/day was not confirmed at 2000 mg/kg bw/day and thus was not considered to be toxicologically significant.
Gross pathological changes in the lungs and stomach of animals killed after 90 days of treatment were seen in all groups including the controls. The lung findings consisted of congestion and/or focal areas of colour change on the pleural surface of one or more lobes. Petechiae on the gastric mucosa were frequently observed in all groups. The incidence of these findings was not related to dosage. Microscopic examination of tissues taken from the control and high-dose (2000 mg/kg bw/day) animals did not show any treatment-related differences between the two groups. Various incidental findings, such as focal aggregates of mononuclear cells within the liver, myocardium and kidney, were found. Pulmonary changes consisted of accumulations of lymphocytes about small blood vessels and air passages, with some extension into interalveolar septa, and mild proliferation of alveolar macrophages. Mild hyperplasia of hepatocytes (hyperplastic nodule) was seen in three control and one treated (2000 mg/kg bw/day) animal, and a spontaneous liposarcoma was seen in the mesentery of one control rat. The NOEL value for males and females was 500 mg/kg bw/day based on the changes in body weights.
This dermal toxicity study in the rat is acceptable and satisfies the guideline requirement for a repeat-dose dermal toxicity study (OECD 411).
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- GLP compliance:
- not specified
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Sourceof test material: Research Institute for Fragrance Materials
- Purity: 99.9%
- Species:
- rat
- Strain:
- other: Charles River CD albino
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Wilmington, MA
- Age at study initiation: approximately 7-9 weeks
- Weight at study initiation: 185-316 g (males) and 158-257 g (females)
- Housing: . Animals were housed in wire-mesh-bottomed stainless-steel cages
- Diet: Powdered Purina Rodent Chow 5001 ad libitum
- Water: fresh municipal tapwater ad libitum
- Acclimation period: 3 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 2°C
- Humidity (%): 50 ± 5%
- Photoperiod (hrs dark / hrs light): 12-hr light/dark cycle - Type of coverage:
- not specified
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Area of exposure: shaved dorsa
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 0, 0.25, 0.5, 1.0, or 2.0 mL/kg (equivalent to 0, 250, 500, 1000, or 2000 mg/kg bw/day) - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Daily
- Dose / conc.:
- 0.25 other: mL/kg/day
- Remarks:
- Equivalent to 250 mg/kg bw/day
- Dose / conc.:
- 0.5 other: mL/kg/day
- Remarks:
- Equivalent to 500 mg/kg bw/day
- Dose / conc.:
- 1 other: mL/kg/day
- Remarks:
- Equivalent to 1000 mg/kg bw/day
- Dose / conc.:
- 2 other: mL/kg/day
- Remarks:
- Equivalent to 2000 mg/kg bw/day
- No. of animals per sex per dose:
- 15 males
15 females - Control animals:
- yes, concurrent no treatment
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Animals were observed daily for changes in appearance and/or behaviour.
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were measured weekly.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes (measured weekly)
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Funduscopic and biomicroscopic examinations were performed on the eyes of all animalsbefore treatment and at wk 13. one drop of a 1% atropine sulphate solution being instilled into each eye to dilate the pupil prior to examination
HAEMATOLOGY: Yes
At wk 6 and 13 blood samples collected from the orbital sinus of five animals of each sex from each group were subjected to the following determinations: haemoglobin. haematocrit. erythrocyte count and total and differential leucocyte counts (Coulter Counter ZBI-6 or manual methods).
CLINICAL CHEMISTRY:
Biochemical analyses, performed on the same samples, comprised fasting serum glucose. blood-urea nitrogen. alkaline phosphatase, glutamic- oxalacetic transaminase and glutamic-pyruvic transaminase (automated methods, Abbott Diagnostics).
URINALYSIS: Yes / No / No data
Urine samples were collected over a 16-hr period at wk 6 and 13 for the recording of volume, colour, transparency, odour, specific gravity, ph. bilirubin, protein, glucose, ketones and occult blood and for a microscopic examination of the urinary sediment (semi-automated or manual methods). - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes. Autopsieswere carried out and the brain, kidneys, liver and gonads were dissected free of fat and weighed. All tissues were preserved in 10”” neutral buffered formalin.
HISTOPATHOLOGY: Yes. Microscopic examination was performed by a veterinary pathologist on representative sections of paraffin-embedded skin (treated and untreated). Adrenals brain, heart, kidneys, liver, lung and bronchi, mesenteric lymph node, pituitary, sternum, spinal cord, testes with epididymides, ovaries, spleen, urinary bladder and nerve with muscle from all control rats and those given the highest dose level. These sections were stained with haematoxylin-eosin. Sternal bone marrow smears from the same groups were stained with May-Griinwald-Giemsa and examined by a haematopathologist. - Statistics:
- Differences between the control group and each of the treated groups were tested for statistical significance using Student’s t test (P < 0.05) when the nature of the data permitted.
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Clinical examinations did not reveal abnormalities or differences among the groups.
- Dermal irritation:
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- No deaths occurred during the treatment period.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Among animals treated with 1.00 or 200 ml/kg, body weights were decreased significantly after 1 wk of treatment and remained so for the duration of the experiment. After 90 days, the mean body-weight gains of rats treated with 0, 0.25. 0.50, 1.00 or 200 ml/kg were 260. 249, 248, 218 and 218 g, respectively, for the males and 98, 93, 87. 78 and 70g for the females (Table 1). The mean body-weight gains of both sexes were depressed among treated animals in a dose-dependent fashion and the decreases were statistically significant at 1.00 and 2.00 ml/kg.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no differences in the amounts of food consumed by the groups; thus, treated animals consumed a significantly greater amount of food relative to the gain in body weight than did the control animals.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Ophthalmological examination revealed no changes in either the fundus or anterior segment.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Haematological results indicated a significant decrease in haemoglobin concentration and white blood cell count at wk 6 and 13 among male rats dosed with 2.00 ml/kg.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Blood biochemistry was not significantly affected among the groups at any of the assessment periods.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Urinary analyses was not significantly affected among the groups at any of the assessment periods.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Significant increases in the relative weights of the brain, kidneys and gonads occurred among rats of both sexes given 200 ml/kg. Relative liver weights were increased at all doses among the females and both absolute and relative liver weights were de creased among the males given 1.00 ml/kg. The elevations in relative organ weights while absolute values remained unchanged were related to decreases in body weight, particularly among animals dosed with 1.00 or 2.00 ml/kg. The decrease in both absolute and relative liver weights in males treated with 1.00 ml/kg was not confirmed at 2.00 ml/kg and thus was not considered to be toxicologically significant.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Gross pathological changes in the lungs and stomach of animals killed after 90 days of treatment were seen in all groups including the controls. The lung findings consisted of congestion and/or focal areas of colour change on the pleural surface of one or more lobes. Petechiae on the gastric mucosa were frequently observed in all groups. The incidence of these findings was not related to dosage.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Microscopic examination of tissues taken from the control and high-dose (2.00 ml/kg) animals did not show any treatment-related differences between the two groups. Various incidental findings, such as focal aggregates of mononuclear cells within the liver, myocardium and kidney, were found. Pulmonary changes consisted of accumulations of lymphocytes about blood vessels and air passages, with some exten- sion into interalveolar septa, and mild proliferation of alveolar macrophages. Mild hyperplasia of hepatocytes (hyperplastic nodule) was seen in three control and one treated (2.00 ml/kg) animal, and a spontaneous liposarcoma was seen in the mesentery of one control rat.
- Histopathological findings: neoplastic:
- not examined
- Dose descriptor:
- NOEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
- Conclusions:
- In a 90 day sub-chronic toxicity study in Charles River CD albino rats, the NOEL value (males/females) for PEA was 500 mg/kg bw/day based on the changes in body weights.
- Executive summary:
In a 90 day sub-chronic toxicity study (Owston and Lough, 1981), PEA (99.9%) was administered to four groups of Charles River CD albino rats (15 animals/sex/group) dermally at dose levels of 0, 0.25, 0.5, 1.0, or 2.0 mL/kg (equivalent to 0, 250, 500, 1000, or 2000 mg/kg bw/day), 7 days per week, for 90 days. No deaths occurred during the treatment period and clinical examinations did not reveal abnormalities or differences among the groups. Among animals treated with 1000 and 2000 mg/kg bw/day body weights were decreased significantly after 1 wk of treatment and remained so for the duration of the experiment. After 90 days, the mean body-weight gains of rats treated with 0, 250, 500, 1000, or 2000 mg/kg bw/day were 260, 249, 248, 218 and 218 g, respectively, for the males and 98, 93, 87, 78 and 70g for the females. The mean body-weight gains of both sexes were depressed among treated animals in a dose-dependent fashion and the decreases were statistically significant at 1000 and 2000 mg/kg bw/day. There were no differences in the amounts of food consumed by the groups; thus, treated animals consumed a significantly greater amount of food relative to the gain in body weight than did the control animals.
Ophthalmological examination revealed no changes in either the fundus or anterior segment. Haematological results indicated a significant decrease in haemoglobin concentration and white blood cell count at week 6 and 13 among male rats dosed with 2000 mg/kg bw/day. Blood biochemistry or urinary analyses was not significantly affected among the groups at any of the assessment periods. Significant increases in the relative weights of the brain, kidneys and gonads occurred among rats of both sexes given 2000 mg/kg bw/day. Relative liver weights were increased at all doses among the females and both absolute and relative liver weights were decreased among the males given 1000 mg/kg bw/day. The elevations in relative organ weights while absolute values remained unchanged were related to decreases in body weight, particularly among animals dosed with 1000 mg/kg bw/day or 2000 mg/kg bw/day. The decrease in both absolute and relative liver weights in males treated with 1000 mg/kg bw/day was not confirmed at 2000 mg/kg bw/day and thus was not considered to be toxicologically significant.
Gross pathological changes in the lungs and stomach of animals killed after 90 days of treatment were seen in all groups including the controls. The lung findings consisted of congestion and/or focal areas of colour change on the pleural surface of one or more lobes. Petechiae on the gastric mucosa were frequently observed in all groups. The incidence of these findings was not related to dosage. Microscopic examination of tissues taken from the control and high-dose (2000 mg/kg bw/day) animals did not show any treatment-related differences between the two groups. Various incidental findings, such as focal aggregates of mononuclear cells within the liver, myocardium and kidney, were found. Pulmonary changes consisted of accumulations of lymphocytes about small blood vessels and air passages, with some extension into interalveolar septa, and mild proliferation of alveolar macrophages. Mild hyperplasia of hepatocytes (hyperplastic nodule) was seen in three control and one treated (2000 mg/kg bw/day) animal, and a spontaneous liposarcoma was seen in the mesentery of one control rat. The NOEL value for males and females was 500 mg/kg bw/day based on the changes in body weights.
This dermal toxicity study in the rat is acceptable and satisfies the guideline requirement for a repeat-dose dermal toxicity study (OECD 411).
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The key study was a read-across study to PEA (CAS No. 60-12-8) and was assigned a Klimisch score of 2.
- System:
- other: Body weight
Repeated dose toxicity: dermal - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- Please see read-across justification.
- Reason / purpose for cross-reference:
- read-across source
- Dose descriptor:
- NOEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
- Conclusions:
- In a 90 day sub-chronic toxicity study in Charles River CD albino rats, the NOEL value (males/females) for PEA was 500 mg/kg bw/day based on the changes in body weights.
- Executive summary:
In a 90 day sub-chronic toxicity study (equivalent or similar to OECD 411), PEA (99.9%) was administered to four groups of Charles River CD albino rats (15 animals/sex/group) dermally at dose levels of 0, 0.25, 0.5, 1.0, or 2.0 mL/kg (equivalent to 0, 250, 500, 1000, or 2000 mg/kg bw/day), 7 days per week, for 90 days. No deaths occurred during the treatment period and clinical examinations did not reveal abnormalities or differences among the groups. Among animals treated with 1000 and 2000 mg/kg bw/day body weights were decreased significantly after 1 wk of treatment and remained so for the duration of the experiment. After 90 days, the mean body-weight gains of rats treated with 0, 250, 500, 1000, or 2000 mg/kg bw/day were 260, 249, 248, 218 and 218 g, respectively, for the males and 98, 93, 87, 78 and 70g for the females. The mean body-weight gains of both sexes were depressed among treated animals in a dose-dependent fashion and the decreases were statistically significant at 1000 and 2000 mg/kg bw/day. There were no differences in the amounts of food consumed by the groups; thus, treated animals consumed a significantly greater amount of food relative to the gain in body weight than did the control animals.
Ophthalmological examination revealed no changes in either the fundus or anterior segment. Haematological results indicated a significant decrease in haemoglobin concentration and white blood cell count at week 6 and 13 among male rats dosed with 2000 mg/kg bw/day. Blood biochemistry or urinary analyses was not significantly affected among the groups at any of the assessment periods. Significant increases in the relative weights of the brain, kidneys and gonads occurred among rats of both sexes given 2000 mg/kg bw/day. Relative liver weights were increased at all doses among the females and both absolute and relative liver weights were decreased among the males given 1000 mg/kg bw/day. The elevations in relative organ weights while absolute values remained unchanged were related to decreases in body weight, particularly among animals dosed with 1000 mg/kg bw/day or 2000 mg/kg bw/day. The decrease in both absolute and relative liver weights in males treated with 1000 mg/kg bw/day was not confirmed at 2000 mg/kg bw/day and thus was not considered to be toxicologically significant.
Gross pathological changes in the lungs and stomach of animals killed after 90 days of treatment were seen in all groups including the controls. The lung findings consisted of congestion and/or focal areas of colour change on the pleural surface of one or more lobes. Petechiae on the gastric mucosa were frequently observed in all groups. The incidence of these findings was not related to dosage. Microscopic examination of tissues taken from the control and high-dose (2000 mg/kg bw/day) animals did not show any treatment-related differences between the two groups. Various incidental findings, such as focal aggregates of mononuclear cells within the liver, myocardium and kidney, were found. Pulmonary changes consisted of accumulations of lymphocytes about small blood vessels and air passages, with some extension into interalveolar septa, and mild proliferation of alveolar macrophages. Mild hyperplasia of hepatocytes (hyperplastic nodule) was seen in three control and one treated (2000 mg/kg bw/day) animal, and a spontaneous liposarcoma was seen in the mesentery of one control rat. The NOEL value for males and females was 500 mg/kg bw/day based on the changes in body weights.
This dermal toxicity study in the rat is acceptable and satisfies the guideline requirement for a repeat-dose dermal toxicity study (OECD 411).
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- GLP compliance:
- not specified
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Sourceof test material: Research Institute for Fragrance Materials
- Purity: 99.9%
- Species:
- rat
- Strain:
- other: Charles River CD albino
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Wilmington, MA
- Age at study initiation: approximately 7-9 weeks
- Weight at study initiation: 185-316 g (males) and 158-257 g (females)
- Housing: . Animals were housed in wire-mesh-bottomed stainless-steel cages
- Diet: Powdered Purina Rodent Chow 5001 ad libitum
- Water: fresh municipal tapwater ad libitum
- Acclimation period: 3 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 2°C
- Humidity (%): 50 ± 5%
- Photoperiod (hrs dark / hrs light): 12-hr light/dark cycle - Type of coverage:
- not specified
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Area of exposure: shaved dorsa
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 0, 0.25, 0.5, 1.0, or 2.0 mL/kg (equivalent to 0, 250, 500, 1000, or 2000 mg/kg bw/day) - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Daily
- Dose / conc.:
- 0.25 other: mL/kg/day
- Remarks:
- Equivalent to 250 mg/kg bw/day
- Dose / conc.:
- 0.5 other: mL/kg/day
- Remarks:
- Equivalent to 500 mg/kg bw/day
- Dose / conc.:
- 1 other: mL/kg/day
- Remarks:
- Equivalent to 1000 mg/kg bw/day
- Dose / conc.:
- 2 other: mL/kg/day
- Remarks:
- Equivalent to 2000 mg/kg bw/day
- No. of animals per sex per dose:
- 15 males
15 females - Control animals:
- yes, concurrent no treatment
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Animals were observed daily for changes in appearance and/or behaviour.
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights were measured weekly.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes (measured weekly)
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Funduscopic and biomicroscopic examinations were performed on the eyes of all animalsbefore treatment and at wk 13. one drop of a 1% atropine sulphate solution being instilled into each eye to dilate the pupil prior to examination
HAEMATOLOGY: Yes
At wk 6 and 13 blood samples collected from the orbital sinus of five animals of each sex from each group were subjected to the following determinations: haemoglobin. haematocrit. erythrocyte count and total and differential leucocyte counts (Coulter Counter ZBI-6 or manual methods).
CLINICAL CHEMISTRY:
Biochemical analyses, performed on the same samples, comprised fasting serum glucose. blood-urea nitrogen. alkaline phosphatase, glutamic- oxalacetic transaminase and glutamic-pyruvic transaminase (automated methods, Abbott Diagnostics).
URINALYSIS: Yes / No / No data
Urine samples were collected over a 16-hr period at wk 6 and 13 for the recording of volume, colour, transparency, odour, specific gravity, ph. bilirubin, protein, glucose, ketones and occult blood and for a microscopic examination of the urinary sediment (semi-automated or manual methods). - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes. Autopsieswere carried out and the brain, kidneys, liver and gonads were dissected free of fat and weighed. All tissues were preserved in 10”” neutral buffered formalin.
HISTOPATHOLOGY: Yes. Microscopic examination was performed by a veterinary pathologist on representative sections of paraffin-embedded skin (treated and untreated). Adrenals brain, heart, kidneys, liver, lung and bronchi, mesenteric lymph node, pituitary, sternum, spinal cord, testes with epididymides, ovaries, spleen, urinary bladder and nerve with muscle from all control rats and those given the highest dose level. These sections were stained with haematoxylin-eosin. Sternal bone marrow smears from the same groups were stained with May-Griinwald-Giemsa and examined by a haematopathologist. - Statistics:
- Differences between the control group and each of the treated groups were tested for statistical significance using Student’s t test (P < 0.05) when the nature of the data permitted.
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Clinical examinations did not reveal abnormalities or differences among the groups.
- Dermal irritation:
- not examined
- Mortality:
- no mortality observed
- Description (incidence):
- No deaths occurred during the treatment period.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Among animals treated with 1.00 or 200 ml/kg, body weights were decreased significantly after 1 wk of treatment and remained so for the duration of the experiment. After 90 days, the mean body-weight gains of rats treated with 0, 0.25. 0.50, 1.00 or 200 ml/kg were 260. 249, 248, 218 and 218 g, respectively, for the males and 98, 93, 87. 78 and 70g for the females (Table 1). The mean body-weight gains of both sexes were depressed among treated animals in a dose-dependent fashion and the decreases were statistically significant at 1.00 and 2.00 ml/kg.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no differences in the amounts of food consumed by the groups; thus, treated animals consumed a significantly greater amount of food relative to the gain in body weight than did the control animals.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Ophthalmological examination revealed no changes in either the fundus or anterior segment.
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Haematological results indicated a significant decrease in haemoglobin concentration and white blood cell count at wk 6 and 13 among male rats dosed with 2.00 ml/kg.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Blood biochemistry was not significantly affected among the groups at any of the assessment periods.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Urinary analyses was not significantly affected among the groups at any of the assessment periods.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Significant increases in the relative weights of the brain, kidneys and gonads occurred among rats of both sexes given 200 ml/kg. Relative liver weights were increased at all doses among the females and both absolute and relative liver weights were de creased among the males given 1.00 ml/kg. The elevations in relative organ weights while absolute values remained unchanged were related to decreases in body weight, particularly among animals dosed with 1.00 or 2.00 ml/kg. The decrease in both absolute and relative liver weights in males treated with 1.00 ml/kg was not confirmed at 2.00 ml/kg and thus was not considered to be toxicologically significant.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Gross pathological changes in the lungs and stomach of animals killed after 90 days of treatment were seen in all groups including the controls. The lung findings consisted of congestion and/or focal areas of colour change on the pleural surface of one or more lobes. Petechiae on the gastric mucosa were frequently observed in all groups. The incidence of these findings was not related to dosage.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Microscopic examination of tissues taken from the control and high-dose (2.00 ml/kg) animals did not show any treatment-related differences between the two groups. Various incidental findings, such as focal aggregates of mononuclear cells within the liver, myocardium and kidney, were found. Pulmonary changes consisted of accumulations of lymphocytes about blood vessels and air passages, with some exten- sion into interalveolar septa, and mild proliferation of alveolar macrophages. Mild hyperplasia of hepatocytes (hyperplastic nodule) was seen in three control and one treated (2.00 ml/kg) animal, and a spontaneous liposarcoma was seen in the mesentery of one control rat.
- Histopathological findings: neoplastic:
- not examined
- Dose descriptor:
- NOEL
- Effect level:
- 500 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
- Conclusions:
- In a 90 day sub-chronic toxicity study in Charles River CD albino rats, the NOEL value (males/females) for PEA was 500 mg/kg bw/day based on the changes in body weights.
- Executive summary:
In a 90 day sub-chronic toxicity study (Owston and Lough, 1981), PEA (99.9%) was administered to four groups of Charles River CD albino rats (15 animals/sex/group) dermally at dose levels of 0, 0.25, 0.5, 1.0, or 2.0 mL/kg (equivalent to 0, 250, 500, 1000, or 2000 mg/kg bw/day), 7 days per week, for 90 days. No deaths occurred during the treatment period and clinical examinations did not reveal abnormalities or differences among the groups. Among animals treated with 1000 and 2000 mg/kg bw/day body weights were decreased significantly after 1 wk of treatment and remained so for the duration of the experiment. After 90 days, the mean body-weight gains of rats treated with 0, 250, 500, 1000, or 2000 mg/kg bw/day were 260, 249, 248, 218 and 218 g, respectively, for the males and 98, 93, 87, 78 and 70g for the females. The mean body-weight gains of both sexes were depressed among treated animals in a dose-dependent fashion and the decreases were statistically significant at 1000 and 2000 mg/kg bw/day. There were no differences in the amounts of food consumed by the groups; thus, treated animals consumed a significantly greater amount of food relative to the gain in body weight than did the control animals.
Ophthalmological examination revealed no changes in either the fundus or anterior segment. Haematological results indicated a significant decrease in haemoglobin concentration and white blood cell count at week 6 and 13 among male rats dosed with 2000 mg/kg bw/day. Blood biochemistry or urinary analyses was not significantly affected among the groups at any of the assessment periods. Significant increases in the relative weights of the brain, kidneys and gonads occurred among rats of both sexes given 2000 mg/kg bw/day. Relative liver weights were increased at all doses among the females and both absolute and relative liver weights were decreased among the males given 1000 mg/kg bw/day. The elevations in relative organ weights while absolute values remained unchanged were related to decreases in body weight, particularly among animals dosed with 1000 mg/kg bw/day or 2000 mg/kg bw/day. The decrease in both absolute and relative liver weights in males treated with 1000 mg/kg bw/day was not confirmed at 2000 mg/kg bw/day and thus was not considered to be toxicologically significant.
Gross pathological changes in the lungs and stomach of animals killed after 90 days of treatment were seen in all groups including the controls. The lung findings consisted of congestion and/or focal areas of colour change on the pleural surface of one or more lobes. Petechiae on the gastric mucosa were frequently observed in all groups. The incidence of these findings was not related to dosage. Microscopic examination of tissues taken from the control and high-dose (2000 mg/kg bw/day) animals did not show any treatment-related differences between the two groups. Various incidental findings, such as focal aggregates of mononuclear cells within the liver, myocardium and kidney, were found. Pulmonary changes consisted of accumulations of lymphocytes about small blood vessels and air passages, with some extension into interalveolar septa, and mild proliferation of alveolar macrophages. Mild hyperplasia of hepatocytes (hyperplastic nodule) was seen in three control and one treated (2000 mg/kg bw/day) animal, and a spontaneous liposarcoma was seen in the mesentery of one control rat. The NOEL value for males and females was 500 mg/kg bw/day based on the changes in body weights.
This dermal toxicity study in the rat is acceptable and satisfies the guideline requirement for a repeat-dose dermal toxicity study (OECD 411).
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The key study was a read-across study to PEA (CAS No. 60-12-8) and was assigned a Klimisch score of 2.
Additional information
There is no short-term (28 days) repeated dose toxicity study for DMPEC. Read-across from an existing dermal sub-chronic (90 days) toxicity study from PEA (CAS No. 60-12-8) was performed.
In a 90 day sub-chronic toxicity study (equivalent or similar to OECD 411), PEA (99.9%) was administered to four groups of Charles River CD albino rats (15 animals/sex/group) dermally at dose levels of 0, 0.25, 0.5, 1.0, or 2.0 mL/kg (equivalent to 0, 250, 500, 1000, or 2000 mg/kg bw/day), 7 days per week, for 90 days. No deaths occurred during the treatment period and clinical examinations did not reveal abnormalities or differences among the groups. Among animals treated with 1000 and 2000 mg/kg bw/day body weights were decreased significantly after 1 wk of treatment and remained so for the duration of the experiment. After 90 days, the mean body-weight gains of rats treated with 0, 250, 500, 1000, or 2000 mg/kg bw/day were 260, 249, 248, 218 and 218 g, respectively, for the males and 98, 93, 87, 78 and 70g for the females. The mean body-weight gains of both sexes were depressed among treated animals in a dose-dependent fashion and the decreases were statistically significant at 1000 and 2000 mg/kg bw/day. There were no differences in the amounts of food consumed by the groups; thus, treated animals consumed a significantly greater amount of food relative to the gain in body weight than did the control animals.
Ophthalmological examination revealed no changes in either the fundus or anterior segment. Haematological results indicated a significant decrease in haemoglobin concentration and white blood cell count at week 6 and 13 among male rats dosed with 2000 mg/kg bw/day. Blood biochemistry or urinary analyses was not significantly affected among the groups at any of the assessment periods. Significant increases in the relative weights of the brain, kidneys and gonads occurred among rats of both sexes given 2000 mg/kg bw/day. Relative liver weights were increased at all doses among the females and both absolute and relative liver weights were decreased among the males given 1000 mg/kg bw/day. The elevations in relative organ weights while absolute values remained unchanged were related to decreases in body weight, particularly among animals dosed with 1000 mg/kg bw/day or 2000 mg/kg bw/day. The decrease in both absolute and relative liver weights in males treated with 1000 mg/kg bw/day was not confirmed at 2000 mg/kg bw/day and thus was not considered to be toxicologically significant.
Gross pathological changes in the lungs and stomach of animals killed after 90 days of treatment were seen in all groups including the controls. The lung findings consisted of congestion and/or focal areas of colour change on the pleural surface of one or more lobes. Petechiae on the gastric mucosa were frequently observed in all groups. The incidence of these findings was not related to dosage. Microscopic examination of tissues taken from the control and high-dose (2000 mg/kg bw/day) animals did not show any treatment-related differences between the two groups. Various incidental findings, such as focal aggregates of mononuclear cells within the liver, myocardium and kidney, were found. Pulmonary changes consisted of accumulations of lymphocytes about small blood vessels and air passages, with some extension into interalveolar septa, and mild proliferation of alveolar macrophages. Mild hyperplasia of hepatocytes (hyperplastic nodule) was seen in three control and one treated (2000 mg/kg bw/day) animal, and a spontaneous liposarcoma was seen in the mesentery of one control rat. The NOEL value for males and females was 500 mg/kg bw/day based on the changes in body weights.
A NOEL of 500mg/kg bw/day in both sexes for DMPEC is also predicted.
Justification for classification or non-classification
Based on available information in the dossier, the substance DMPEC (CAS No. 103-05-9) does not need to be classified for specific target organ toxicity (repeated) when considering the criteria outlined in Annex I of 1272/2008/EC, based on the results of the read-across study from PEA (CAS No. 60-12-8).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.